A Phase 3 interventional study of Rifaximin and Placebo in Non-Constipation Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 96 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Abdominal Pain with a site in United States — 23 open to participants now, 24 under way, 1 of them phase 3. Abdominal Pain · United States.
Among the 158 studies in Abdominal Pain with a site in United States, this one is the 8th largest by enrollment of the 133 interventional ones that give a count, is one of 9 that started in 2008, is one of 11 in phase 3, and was the 25th registered.
388 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.
Browse Abdominal Pain studies →23 of the 158 studies in Abdominal Pain with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 6–17
Baylor College of Medicine · Sites in United States
Ages 7–12
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
Kiwi Health Inc · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Abdominal Pain studies recruiting now, 13 (39%) set no upper age limit and 17 (52%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 31 · Phase 3 15 · Phase 4 11
First in 1996; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 623 is above the median of 70 across 291 interventional studies indexed under Abdominal Pain.
Median enrollment 61 across the 133 interventional studies, 94 across the 24 observational. Of the 119 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 158 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 4 studies filed under Abdominal Pain — fewer than ten, so there is no comparison to draw.
10 of the studies in Abdominal Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07174609Johns Hopkins UniversityScrambler Therapy in Chronic Pancreatitis | 2026-12-01 |
| NCT07649720AnX Robotica Corp.NaviCam Patency Capsule to Verify Gastrointestinal Patency | 2026-12-15 |
| NCT06647615Mayo ClinicA Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease | 2026-12-31 |
| NCT07117032Case Comprehensive Cancer CenterSimulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain | 2027-02 |
| NCT06706778Yale UniversityThe Mechanism Underlying the Analgesic Effect of the Music of IBS Pain | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 158 studies in Abdominal Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Drug: Placebo
Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Drug: Rifaximin
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"
Time frame: 4 weeks
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."
Time frame: 4 weeks
| Milestone | Placebo | Rifaximin |
|---|---|---|
| Started | 314 | 309 |
| Completed | 292 | 283 |
| Not completed | 22 | 26 |
| Withdrew: Adverse event | 7 | 8 |
| Withdrew: Withdrawal by subject | 8 | 8 |
| Withdrew: Lost to follow-up | 7 | 8 |
| Withdrew: Noncompliance | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"
| percentage of responders | Placebo | Rifaximin |
|---|---|---|
| Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). | 31.2 | 40.8 |
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."
| percentage of responders | Placebo | Rifaximin |
|---|---|---|
| Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). | 28.7 | 39.5 |
Collected over 12 weeks. Adverse events were collected during the 2-week treatment period and during the 10-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 8/314 (2.5%) | 101/314 (32.2%) |
| Rifaximin | — | 3/309 (1%) | 103/309 (33.3%) |
| Event | Placebo | Rifaximin |
|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/314 | 1/309 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/314 | 1/309 |
| Alcohol withdrawal syndromePsychiatric disorders | 0/314 | 1/309 |
| Rectal haemorrhageGastrointestinal disorders | 1/314 | 0/309 |
| Small intestinal obstructionGastrointestinal disorders | 1/314 | 0/309 |
| CholecystitisHepatobiliary disorders | 1/314 | 0/309 |
| Cholecystitis acuteHepatobiliary disorders | 1/314 | 0/309 |
| GastroenteritisInfections and infestations | 1/314 | 0/309 |
| Fracture nonunionMusculoskeletal and connective tissue disorders | 1/314 | 0/309 |
| AmnesiaNervous system disorders | 1/314 | 0/309 |
| Event | Placebo | Rifaximin |
|---|---|---|
| Abdominal painGastrointestinal disorders | 23/314 | 19/309 |
| NauseaGastrointestinal disorders | 13/314 | 22/309 |
| HeadacheNervous system disorders | 16/314 | 18/309 |
| NasopharyngitisInfections and infestations | 18/314 | 7/309 |
| DiarrhoeaGastrointestinal disorders | 15/314 | 14/309 |
| SinusitisInfections and infestations | 12/314 | 7/309 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 12/314 | 8/309 |
| VomitingGastrointestinal disorders | 8/314 | 11/309 |
| FlatulenceGastrointestinal disorders | 11/314 | 6/309 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/314 | 9/309 |
The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 275 | 274 | 549 |
| >=65 years | 38 | 34 | 72 |
| Age, Continuous(years) | Placebo | Rifaximin | Total |
|---|---|---|---|
| Mean | 45.5 ± 14.6 | 46.2 ± 15.0 | 45.8 ± 14.8 |
| Sex: Female, Male(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| Female | 222 | 235 | 457 |
| Male | 92 | 74 | 166 |
| Race (NIH/OMB)(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 30 | 24 | 54 |
| White | 280 | 281 | 561 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →